Trioday Tablet

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Trioday are:

Elevated levels of serum amylase

Blood in urine

Increased transaminase levels in the blood

Cough

Headache

Nausea

Insomnia (difficulty in sleeping)

Weakness

Depression Diarrhea

Rash

Body Pain

Fever

Decreased white blood cell count (neutrophils)

Peripheral neuropathy (tingling and numbness of the feet and hands)

Pneumonia

Increased triglyceride level in the blood

Anxiety

Vomiting

Indigestion

As directed by your physician, take this medication for the prescribed amount of time. Eat it all at once. Avoid chewing, crushing, or breaking it. The Trioday Tablet should be taken without food. Trioday Tablets should be taken as directed by your physician or on an empty stomach. For optimal safety, take this medication exactly as prescribed by your doctor. Take the entire Trioday Tablet with a glass of water.

The active ingredients in Trioday tablets are efavirenz, lamivudine, and tenofovir disoproxil fumarate. Efavirenz belongs to the class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), which includes antiretroviral drugs. The antiretroviral or antiviral drug lamivudine with tenofovir disoproxil fumarate is a member of the class of drugs known as nucleotide reverse transcriptase inhibitors (NRTI). They function by stopping the HIV from growing, which lowers the infection's level in your body. Also, they raise the number of CD4 cells in your blood, which are white blood cells that fight infection. By inhibiting the reverse transcriptase enzyme, which is required for viral replication, nucleoside reverse transcriptase inhibitors (NRTIs), such as lamivudine and tenofovir disoproxil fumarate, prevent HIV from proliferating. Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), further reduces HIV replication by binding directly to the reverse transcriptase enzyme and altering its structure to prevent it from working. Together, these drugs reduce the viral load and stop HIV infection from spreading.

It is advised to use effective birth control methods to avoid pregnancy. Some drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine. Moreover, this medicine may pass to the unborn baby.

Consult your doctor if you observe symptoms such as abdominal pain, loss of appetite, dark urine, or yellowing of the eyes or skin. These symptoms indicate the presence of Jaundice in the body.

It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with Trioday medicine. There are chances that many drugs can interact, and some drugs should not be used together.

Inform your healthcare expert in case of a history of severe blood infection, active tuberculosis, liver problems, or any serious health disorder.

Arribas, J. R., et al. (2008). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: 96-week analysis. Journal of Acquired Immune Deficiency Syndromes, 47(1), 74–78.

Cassetti, I., et al. (2006). The safety and efficacy of tenofovir DF (TDF) + lamivudine (3TC) + efavirenz (EFV) through 5 years in antiretroviral-naïve patients. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK.

DeJesus, E., et al. (2009). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral naïve patients: 96-week analysis. Journal of Acquired Immune Deficiency Syndromes, 47(1), 74–78.

Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China, (n.d.). PubMed. Retrieved from the PubMed database.

Gallant, J., et al. (2005). Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral naive HIV infected patients: a 4-year follow-up.
Pujari, S., Dravid, A., Gupte, N., Joshi, K., & Bele, V. (2008). Effectiveness and safety of a generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV 1 infected patients in Western India. Medscape Journal of Medicine, 10(8), 196.